High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma

H. A.F. Stessman, A. Lulla, T. Xia, A. Mitra, T. Harding, A. Mansoor, C. L. Myers, B. G. Van Ness, N. G. Dolloff

Research output: Contribution to journalLetterpeer-review

10 Scopus citations
Original languageEnglish (US)
Pages (from-to)2263-2267
Number of pages5
Issue number11
StatePublished - Nov 2014

Bibliographical note

Funding Information:
BVN receives research support from Millennium Pharmaceuticals, Inc., Cambridge, MA, and Onyx Pharmaceuticals, Inc., South San Francisco, CA, USA. The remaining authors declare no conflict of interest.

Cite this